Correction to: Matrix Metalloproteinases and Glaucoma Treatment,by Weinreb,R.N.,Robinson,M.R.,Dibas,M. and Stamer,W.D. J Ocul Pharmacol Ther 2020;36(4):208–228. DOI: 10.1089/jop.2019.0146

In the MAY 2020 issue of Journal of Ocular Pharmacology and Therapeutics (vol. 36, no. 4; 208–222) the article entitled Matrix Metalloproteinases and Glaucoma Treatment by Weinreb et al. requires correction. The legend for Figure 8 has been updated.

On page 222, the legend for Figure 8 originally read:

FIG. 8. Bimatoprost SR is a first-in-class, sustainedrelease, bimatoprost implant that is administered intracamerally. (A) Photograph of an implant (10-mg dose strength; arrow) superimposed on an image of a dime. The implant is similar in size to the ‘‘i’’ in Liberty on the dime; the shape is cylindrical (radius*200 mm, length*1.1 mm). (B) Photograph of a single-use, 28-gauge applicator used for implant administration.

This has been corrected to read:

FIG. 8. Bimatoprost SR is a first-in-class, sustainedrelease, bimatoprost implant that is administered intracamerally. (A) Photograph of an implant (10-mg dose strength; arrow) superimposed on an image of a dime. The implant is similar in size to the ‘‘i’’ in Liberty on the dime; the shape is cylindrical (diameter*200 mm, length*1.1 mm). (B) Photograph of a single-use, 28-gauge applicator used for implant administration.

The online version of the article has been corrected. The authors apologize for the error.